Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31537527 | 1.00 | ESR1 (0.40) | ESR1ESR2ALDH1A1TDP2BRD4 | |
| SCHEMBL12718645 | 0.85 | BRD4 (0.39) | ESR1ESR2BRD4MAPTLMNA | |
| SCHEMBL3310487 | 0.85 | TDP2 (0.40) | ALDH1A1TDP2BRD4MAPTMEN1 | |
| SCHEMBL30663973 | 0.85 | TDP2 (0.40) | ALDH1A1TDP2BRD4MAPTMEN1 | |
| SCHEMBL13259212 | 0.84 | OPRM1 (0.43) | ESR1ESR2ALDH1A1BRD4MAPT | |
| SCHEMBL22018267 | 0.83 | KDM4E (0.40) | ALDH1A1TDP2BRD4MAPTMEN1 | |
| SCHEMBL3498263 | 0.82 | ALDH1A1 (0.36) | ALDH1A1TDP2BRD4MAPTMEN1 | |
| SCHEMBL16595774 | 0.82 | OPRM1 (0.46) | ESR1ESR2BRD4MAPTMEN1 | |
| SCHEMBL22898433 | 0.82 | LMNA (0.42) | ESR1ESR2ALDH1A1BRD4MAPT | |
| SCHEMBL13259217 | 0.81 | CYP4F2 (0.45) | ESR1ESR2BRD4SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583972-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230132370-A9 | CRYSTAL FORMS OF THIAZOLE COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230132370-A9 | CRYSTAL FORMS OF THIAZOLE COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-3566749-A1 | THIAZOLE DERIVATIVE AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132370-A9 | CRYSTAL FORMS OF THIAZOLE COMPOUND AND APPLICATION THEREOF | ZC3HAV1L, ZC3HAV1, RPL35 | ESR1 4507/4885ESR2 3604/4885ALDH1A1 1605/4885 |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885ESR2 1/4885ALDH1A1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.